Vera Therapeutics (VERA) announced it has submitted a Biologics License Application to the U.S. FDA through the Accelerated Approval Program for atacicept for the treatment of adults with immunoglobulin A nephropathy. If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN; potential FDA approval in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target lowered to $52 from $53 at JPMorgan
- Vera Therapeutics’ Atacicept Shows Promising Phase 3 Results and Regulatory Progress, Earning Buy Rating
- Vera Therapeutics Announces Promising Phase 3 Trial Results
- Vera Therapeutics reports ‘positive’ data from ORIGIN Phase 3 trial of atacicept
- Vera Therapeutics Reports Increased Losses Amid R&D Expansion